The Quantellect read.As of Nov 19, 2026, 21 active firms cover Doximity Inc: 7 rate it Buy or better, 12 sit at Neutral, and 2 rate it Sell or worse, a neutral consensus. Targets range widely, $18.00 to $47.00 (about 2.6x), a sign of real disagreement on valuation. The average target of $27.74 sits 10% below the current $30.71. The rating mix has stayed broadly stable, with Buy-side ratings easing from 8 to 7 over recent months. On the fundamentals, the Street sees consensus EPS building from about $0.26 next quarter toward $1.55 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS21 active firms
Neutral
Strong Buy15%
Buy629%
Neutral1257%
Sell210%
Strong Sell00%
Based on 21 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$27.74
-9.7% downside
Average target across 19 active firms as of Nov 19, 2026 vs $30.71 current
Highest Target$47.00
Average Target$27.74
Lowest Target$18.00
Detailed analyst forecasts for DOCS
Showing 1–21 of 21 named analysts shown · 21 active firms in the rating projection
As of Nov 19, 2026, 7 of 21 active firms rate DOCS a Buy (12 Neutral, 2 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
DOCS EPS & revenue forecast
EPS · NEXT QUARTER
$0.26
Range $0.24 – $0.30 · 17 analysts · -1% YoY
Next period, 17 analysts expect Doximity Inc to earn $0.26 a share (range $0.24 – $0.30), versus $0.26 a year earlier. Full-year consensus is $1.35, growing to $1.55 the year after.
REVENUE · NEXT QUARTER
$153.9M
Range $150.2M – $157.1M · 17 analysts · +6% YoY
Revenue is expected to reach $153.9M (range $150.2M – $157.1M), +5.9% year-over-year. Full-year consensus is $680.3M, rising to $722.8M next year.
Top analysts covering Doximity Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on DOCS.
#1
Richard Close
Canaccord Genuity · Rank #249
Buy
$36.00+17.2% to target
Overall win rate
37%
+ Follow
#2
Brian Tanquilut
Jefferies · Rank #280
Neutral
$19.00-38.1% to target
Overall win rate
46%
+ Follow
#3
Brian Peterson
Raymond James · Rank #539
Buy
$38.00+23.7% to target
Overall win rate
24%
+ Follow
#4
Scott Schoenhaus
Keybanc · Rank #540
Neutral
No targeton DOCS
Overall win rate
30%
+ Follow
#5
Scott Berg
Needham · Rank #575
Buy
$41.00+33.5% to target
Overall win rate
22%
+ Follow
DOCS stock forecast FAQ
What is DOCS's average 12-month price target?+
The 19 active firms with a live target average $27.74 for Doximity Inc over the next 12 months, ranging from a $47.00 high to a $18.00 low, as of Nov 19, 2026.
Is DOCS stock a Buy, Sell or Neutral right now?+
The current consensus is Neutral. Of the 21 active firms as of Nov 19, 2026, 7 rate it Buy or Strong Buy, 12 rate it Neutral, and 2 rate it Sell or Strong Sell.
What are the highest and lowest price targets for DOCS?+
The Street-high target is $47.00 (Piper Sandler), and the Street-low is $18.00 (Wells Fargo). The average of all 19 active-firm targets is $27.74.
How many active Wall Street firms cover DOCS?+
21 active firms have a recognized rating on Doximity Inc as of Nov 19, 2026, and 19 active firms carry a live 12-month price target.
Who is the most accurate analyst covering DOCS?+
Among analysts who currently cover DOCS, Richard Close of Canaccord Genuity has the strongest overall Quantellect track record (Rank #249). Their current call is Buy with a $36.00 target.
What is Doximity Inc's projected EPS for next quarter?+
The consensus estimate is $0.26 per share (range $0.24 – $0.30) across 17 analysts. Full-year EPS is projected at $1.35, rising to $1.55 the following year.
How much revenue is Doximity Inc expected to report next quarter?+
Consensus revenue is $153.9M (range $150.2M – $157.1M). Full-year revenue is projected at $680.3M, growing to $722.8M next year.
Have analysts been upgrading or downgrading DOCS lately?+
As of Nov 19, 2026, 7 of 21 active firms rate DOCS a Buy (12 Neutral, 2 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their DOCS calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.